Fig. 1
From: Selective SERCA2a activator as a candidate for chronic heart failure therapy
Chemical structure and Na+/K+ ATPase inhibition. A Chemical structures of compound 8 in comparison to istaroxime and its metabolite, PST3093. B Concentration–response curve for INaK inhibition by compound 8 (N = 3, n = 21), in comparison to PST3093 and istaroxime (modified from [12] in rat LV myocytes; INaK recording under increasing concentration of compound 8 and finally ouabain (OUA as reference) is shown on the right. Data are the mean ± SEM